Advertisement
ANIX vs TNYA
Which Stock Would AI Choose? Anixa Biosciences (ANIX) vs. Tenaya Therapeutics (TNYA) Stock Comparison
Key Takeaways
- ANIX (Anixa Biosciences) is an oncology-focused biotech advancing a breast cancer vaccine and a CAR-T (chimeric antigen receptor T-cell) therapy for ovarian cancer, while TNYA (Tenaya Therapeutics) develops gene therapies for genetic heart disease.
- Both companies are clinical-stage and pre-revenue, meaning their valuations are driven primarily by pipeline milestones, trial data, and cash runway rather than sales.
- Recent market activity shows ANIX trading in the low-to-mid single digits with a sub-$200 million market cap, while TNYA trades below $1 with a comparable market capitalization, reflecting distinct risk and liquidity profiles.
- Analyst coverage skews positive on both names, with buy ratings and wide price targets that highlight substantial upside but also significant binary, data-driven risk.
- TNYA has secured a catalyst-rich path, including regulatory designations and a collaboration with Alnylam Pharmaceuticals, whereas ANIX is focused on early-stage clinical execution across its cancer programs.
- For further detail, explore ANIX Major News and ANIX Today's Price Move, as well as TNYA Major News and TNYA Today's Price Move.
- Readers interested in AI-driven trading signals can also explore Trending AI Robots for automated stock analysis.
Introduction
Investors evaluating small-cap biotechnology often weigh pipeline quality, clinical catalysts, and financial durability against valuation. ANIX and TNYA sit at the intersection of these considerations, but pursue very different disease areas: oncology versus cardiovascular gene therapy. This stock comparison is most relevant to growth-oriented traders and biotech specialists assessing relative performance and market positioning between two clinical-stage names with meaningful catalyst potential but limited near-term revenue. Understanding how each company's recent news flow, sector exposure, and capital position shape sentiment can help investors compare risk-adjusted opportunity more clearly.
ANIX Overview and Recent Performance
ANIX, or Anixa Biosciences, Inc., is a biotechnology company developing therapies and vaccines targeting cancer. Its lead programs include a preventive breast cancer vaccine developed with Cleveland Clinic and a CAR-T cell therapy for ovarian cancer conducted in partnership with Moffitt Cancer Center. Recent weeks have brought steady clinical execution news, including the administration of additional CAR-T doses in an ongoing Phase 1 trial, a submitted protocol amendment, and plans for a Phase 2 breast cancer vaccine study. The stock has traded in a range roughly between $2.30 and $5.50 over the trailing year, with recent prices near the lower-middle of that band. Sell-side analysts have maintained buy ratings with price targets spanning roughly $6 to $14, reflecting a wide dispersion of expectations around early-stage clinical outcomes. Sentiment has been supported by insider purchases and pipeline progress, though the absence of product revenue keeps the equity highly sensitive to trial news.
TNYA Overview and Recent Performance
TNYA, or Tenaya Therapeutics, Inc., is a clinical-stage biotech focused on discovering and developing potentially curative therapies for the underlying causes of heart disease. Its pipeline includes TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM), and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC), along with the small-molecule candidate TN-301. In recent months the company reported positive interim trial data, received regulatory designations supporting its TN-401 program, and entered a multi-target research collaboration with Alnylam Pharmaceuticals that included an upfront payment and potential milestones. The stock trades below $1, within a trailing 52-week range of roughly $0.53 to $2.35, and has experienced notable volatility around data readouts. Analysts largely hold buy ratings, though price targets vary widely. A strengthened cash position extending its runway into the second half of 2027 has been a key stabilizing factor.
Trending AI Robots
Tickeron's Trending AI Robots page curates a selection of automated trading systems from a broader library of hundreds of AI-powered bots that monitor thousands of tickers. Each robot operates with its own trading style, strategy, timeframe, performance history, and watchlist of stocks, which means no two bots approach the market identically. Only the systems best aligned with current market conditions earn a place in this featured section, offering traders a filtered view of strategies that are performing well right now. By reviewing the curated list, investors can quickly identify bots whose statistical profiles and risk parameters may match their own objectives across equities like those discussed in this comparison. Explore the Trending AI Robots section to see which automated strategies are currently leading.
Head-to-Head Comparison
The most fundamental contrast between ANIX and TNYA is therapeutic focus. ANIX concentrates on oncology prevention and treatment, a broad field with substantial addressable markets but intense competition. TNYA targets genetic cardiomyopathies, a more specialized space where gene therapy offers the prospect of single-dose, disease-modifying treatment. Growth drivers also differ: ANIX is leveraged to early-stage cancer vaccine and CAR-T readouts, while TNYA is further along with interim efficacy data, regulatory designations, and a non-dilutive collaboration that bolsters its balance sheet. On risk factors, both face binary clinical outcomes and financing needs, but TNYA's sub-$1 share price introduces additional listing-compliance and volatility considerations relative to ANIX's higher nominal price. Recent momentum has favored ANIX's steadier clinical cadence, whereas TNYA's larger swings reflect a heavier dependence on discrete data events. Sector exposure and market sentiment thus present a trade-off between ANIX's broad oncology opportunity and TNYA's differentiated, catalyst-dense cardiology pipeline.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely assign a more favorable relative posture to TNYA in the current environment. The company benefits from a catalyst-rich near-term calendar, validated interim data, and a strengthened cash position that reduces immediate dilution risk, factors that tend to support trend consistency and stability in AI-driven scoring. That said, the assessment is probabilistic rather than definitive: ANIX's steadier price action and positive insider activity offer a contrasting stability profile that could rank more favorably on measures of lower short-term volatility. The AI's preference therefore reflects a trade-off between TNYA's event-driven upside and ANIX's comparatively calmer technical footing, with the balance currently tilting modestly toward TNYA on the strength of its catalysts and financial runway.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANIX is a Hold and TNYA is a Buy.
ANIX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for ANIX moved below the 200-day moving average on November 02, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for ANIX moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 45 of 53 cases where ANIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 85%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ANIX as a result. In 88 of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANIX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
ANIX broke above its upper Bollinger Band on October 27, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for ANIX just turned positive on October 22, 2026. Looking at past instances where ANIX's MACD turned positive, the stock continued to rise in 40 of 47 cases over the following month. The odds of a continued upward trend are 85%.
ANIX moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ANIX crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +9.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANIX advanced for three days, in 180 of 221 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 28 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. ANIX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.627) is normal, around the industry mean (3.498). P/E Ratio (-9.922) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (384.615) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ANIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
TNYA in upward trend: price may jump up because it broke its lower Bollinger Band on November 05, 2026
TNYA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 32 of 35 cases where TNYA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where TNYA's RSI Indicator exited the oversold zone, 31 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 61 cases where TNYA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Moving Average Convergence Divergence (MACD) for TNYA just turned positive on October 28, 2026. Looking at past instances where TNYA's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +24.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where TNYA advanced for three days, in 210 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TNYA as a result. In 73 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TNYA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for TNYA entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 9 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 60 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.164) is normal, around the industry mean (3.498). P/E Ratio (-0.706) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (94.340) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 90 (best 1 - 100 worst), indicating slightly worse than average price growth. TNYA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TNYA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ANIX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 25 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 68 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 51 | |
P/E GROWTH RATING 1..100 | 28 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ANIX | TNYA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 82% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 78% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 84% |
| TrendMonth ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| Advances ODDS (%) | 8 days ago 81% | 3 days ago 86% |
| Declines ODDS (%) | 2 days ago 82% | 9 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Aroon ODDS (%) | N/A | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANIX’s FA Score shows that 1 FA rating(s) are green while TNYA’s FA Score has 1 green FA rating(s).
- ANIX’s FA Score: 1 green, 4 red.
- TNYA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANIX’s TA Score shows that 4 TA indicator(s) are bullish while TNYA’s TA Score has 5 bullish TA indicator(s).
- ANIX’s TA Score: 4 bullish, 6 bearish.
- TNYA’s TA Score: 5 bullish, 3 bearish.
Price Growth
ANIX (@Biotechnology) experienced а +0.16% price change this week, while TNYA (@Biotechnology) price change was +2.86% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
ANIX is expected to report earnings on Jan 06, 2027.
TNYA is expected to report earnings on Mar 23, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ANIX and
Correlation & Price change
A.I.dvisor indicates that over the last year, ANIX has been loosely correlated with PRME. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ANIX jumps, then PRME could also see price increases.
| Ticker / NAME | Correlation To ANIX | 1D Price Change % | ||
|---|---|---|---|---|
| ANIX | 100% | -3.16% | ||
| PRME - ANIX | 45% Loosely correlated | -9.30% | ||
| TNYA - ANIX | 43% Loosely correlated | -5.94% | ||
| RXRX - ANIX | 42% Loosely correlated | -6.70% | ||
| RCKT - ANIX | 41% Loosely correlated | -3.16% | ||
| CRSP - ANIX | 41% Loosely correlated | -9.77% | ||
More | ||||
TNYA and
Correlation & Price change
A.I.dvisor indicates that over the last year, TNYA has been loosely correlated with ANIX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if TNYA jumps, then ANIX could also see price increases.
| Ticker / NAME | Correlation To TNYA | 1D Price Change % | ||
|---|---|---|---|---|
| TNYA | 100% | -5.94% | ||
| ANIX - TNYA | 43% Loosely correlated | -3.16% | ||
| VCYT - TNYA | 40% Loosely correlated | -7.18% | ||
| MIST - TNYA | 39% Loosely correlated | -10.27% | ||
| BNTC - TNYA | 39% Loosely correlated | -5.98% | ||
| SLDB - TNYA | 39% Loosely correlated | +2.14% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| CRCD | 3.08 | 0.23 | +8.07% |
| T-REX 2X Inverse CRCL Daily Target ETF (CRCD) | |||
| CET | 56.57 | -0.16 | -0.28% |
| Central Securities Corp | |||
| SMAY | 27.87 | -0.12 | -0.43% |
| FT Vest U.S. Small Cap Moderate Buffer ETF - May (SMAY) | |||
| TLTP | 19.42 | -0.22 | -1.12% |
| Amplify TLT U.S. Treasury 12% Option Income ETF (TLTP) | |||
| EDD | 5.41 | -0.14 | -2.52% |
| Morgan Stanley Emerging Markets Domestic Debt Fund | |||